
ZZW-115
CAS No. 801991-87-7
ZZW-115( —— )
Catalog No. M37627 CAS No. 801991-87-7
ZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 277 | In Stock |
![]() ![]() |
5MG | 426 | In Stock |
![]() ![]() |
10MG | 630 | In Stock |
![]() ![]() |
25MG | 966 | In Stock |
![]() ![]() |
50MG | 1260 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameZZW-115
-
NoteResearch use only, not for human use.
-
Brief DescriptionZZW-115 is a potent NUPR1 inhibitor with a Kd of 2.1 μM and is a derivative of Trifluoperazine (TFP).
-
DescriptionZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. Anticancer activity.
-
In VitroZZW-115 (0.1-33 μM; 72 hours) is efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).ZZW-115 (0-100 μM; 24-72 hours) is efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).ZZW-115 induces pancreatic cell death by necrosis and apoptosis. ZZW-115 treatment induces a decrease in ATP production and induces a ROS overproduction.LDH release is significantly higher in ZZW-115-treated cells (MiaPaCa-2, 02-063, LIPC, Foie8b, and HN14 cells) than in control cells in a concentration-dependent manner. Similarly, caspase 3/7 activity is also greater in ZZW-115-treated cells. These experiments demonstrated that ZZW-115 exerted both pronecrotic and proapoptotic effects.Cell Viability Assay Cell Line:ANOR cells, MiaPaCa-2, 02-063, 01008, LIPC, 02136, HN01,01046, AOIPC, Foie8b, HN14 cells Concentration:0.1- 33 μM Incubation Time:72 hours Result:Was efficient in killing cancer cells, with an IC50 in the range of 0.84 μM (ANOR) to 4.93 μM (HN14).Cell Proliferation Assay Cell Line:U87, A375, U2OS, SaOS-2, HT29, SK-CO-1, LS174T, H1299 and H358, HepG2, PC3, THP-1, Daudi, Jurkat and MDA-MB-231 cells Concentration:0-100 μM Incubation Time:24 or 72 hours Result:Was efficient to kill these tumor cells with an IC50 in the range of 0.42 μM (Hep2G cells) to 7.75 μM (SaOS-2 cells).
-
In VivoZZW-115 (0.5-5 mg/kg; injection; daily for 30 days) inhibits the growth of pancreatic xenografted tumors.ZZW-115 (5 mg/kg for 30 days; immunocompetent C57BL/6 mice were orthotopically implanted with Panc02 cells) treatment shows the tumor size is almost unmeasurable in some cases.Animal Model:NMRI-Foxn1nu/Foxn1nu mice (nude mice) xenografted with MiaPaCa-2 cells Dosage:5, 2.5, 1.0, or 0.5 mg/kg Administration: Injection, daily for 30 days Result:When the mice were injected with 5 mg/kg ZZW-115, the tumors stopped growing a few days after treatment and their size decreased progressively, almost disappearing at the end of the treatment.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number801991-87-7
-
Formula Weight464.59
-
Molecular FormulaC24H31F3N4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(CCN1CCN(CCN(C)C)CC1)N2C=3C(SC=4C2=CC=CC4)=CC=C(C(F)(F)F)C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Santofimia-Casta?o P, et al. Ligand-based design identifies a potent NUPR1 inhibitor exerting anticancer activity via necroptosis. J Clin Invest. 2019;129(6):2500-2513. Published 2019 Mar 28.?
molnova catalog



related products
-
Ameltolide
Ameltolide is an anticonvulsant agent. It has been shown to be effective at inhibiting seizures in animal models.
-
VULM 1457
VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.
-
Dalbavancin Impurity
Dalbavancin is a semisynthetic lipoglycopeptide that was designed to improve upon the natural glycopeptides currently available, vancomycin and teicoplanin.